# FDA Clears United Therapeutics for Phase 1 Trial of PAH Candidate

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/43009
Published: 2026-10-28T22:16:26.000Z
Updated: 2026-10-28T22:16:26.000Z
Section: Regulation

> The open-label study will use a single ascending dose design in healthy participants and assess safety, tolerability and pharmacokinetics.

The U.S. Food and Drug Administration cleared United Therapeutics to conduct a Phase 1 trial of treprostinil-iloprost SMI, its candidate for pulmonary arterial hypertension.

The open-label study will use a single ascending dose design in healthy participants. It will assess the candidate’s safety, tolerability and pharmacokinetics.